FX1 | B2010

FX1 is a potent B cell lymphoma 6 (BCL6) inhibitor. FX1 displays 10-fold greater potency than endogenous corepressors and binds an essential region of the BCL6 lateral groove. FX1 disrupts formation of the BCL6 repression complex, reactivated BCL6 target genes, and mimics the phenotype of mice engineered to express BCL6 with corepressor binding site mutations.

FX1 is a potent B cell lymphoma 6 (BCL6) inhibitor. FX1 displays 10-fold greater potency than endogenous corepressors and binds an essential region of the BCL6 lateral groove. FX1 disrupts formation of the BCL6 repression complex, reactivated BCL6 target genes, and mimics the phenotype of mice engineered to express BCL6 with corepressor binding site mutations.

B2010 | FX1 DataSheet

Alternate Name/Synonyms: (5Z)-5-(5-Chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4-oxo-2-thioxo-3-thiazolidinepropanoic acid

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 1426138-42-2

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₁₄H₉ClN₂O₄S₂

Molecular Weight: 368.81

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent B cell lymphoma 6 (BCL6) inhibitor

MDL Number: N/A

PubChem CID: 66488970

SMILES: C1=CC2=C(C=C1Cl)C(=C3C(=O)N(C(=S)S3)CCC(=O)O)C(=O)N2

InChi: InChI=1S/C14H9ClN2O4S2/c15-6-1-2-8-7(5-6)10(12(20)16-8)11-13(21)17(14(22)23-11)4-3-9(18)19/h1-2,5H,3-4H2,(H,16,20)(H,18,19)/b11-10-

InChi Key: VISHSGZPGQKEFX-KHPPLWFESA-N